Kilitch Drugs(India) Peer Comparison

Snapshot Summary

Kilitch Drugs (India) Ltd. demonstrates strong growth potential with a respectable profitability profile, making it competitive within the pharmaceuticals sector, particularly against peers with higher valuations. However, some companies stand out as better value picks and stronger performers overall.

• Kilitch Drugs shows solid revenue growth and good return metrics compared to peers.
• Sun Pharmaceuticals and Divi's Laboratories are among the most overvalued, while Kilitch presents a more attractive valuation based on its growth.
• Cipla and Dr. Reddy's Laboratories rank highly in terms of profitability and efficiency.

• Dr. Reddy's Laboratories Ltd.: High ROE (21.76%), strong EPS growth and low PE (15.50) make it a standout.
• Cipla Ltd.: Impressive profitability metrics with a reasonable PE (23.73) and solid growth.
• Kilitch Drugs (India) Ltd.: Strong revenue growth (YoY: 28.47%) and decent profitability metrics (ROE: 8.43%).

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
KILITCH	₹378.10	₹661.65Cr	23.63	13.20%	17.31%	0.24
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Kilitch Drugs(India) Peer Comparison

Snapshot Summary